Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2006

View Archived Issues

CP-724714 pharmacokinetics assessed in humans and population model

Pharmacokinetics of KS-01017 formulations and administration routes compared

Receptor occupancy, pharmacokinetics and safety of lecozotan forms investigated

Miraxion improves stress hormone transport through the blood-brain barrier

DITPA studied in new phase II trial to treat elevated cholesterol levels

Targeting Ang-2 for inflammatory vasculopathies

Phase III trial investigates Ventavis with sildenafil citrate for PAH

Lilly studies enzastaurin for glioblastoma multiforme in new phase III study

X-Cell Medical begin new ETHOS drug-eluting stent trial

New phase I study for intravenous peramivir

Guidant studies fully bioabsorbable everolimus-eluting stent platform

New phase II trial investigates RG-2417 for bipolar depression

Traditional approval for Viread and Truvada

Novartis executes license option with Emisphere for oral PTH

Alchemia and Meditech Research announce merger

PK and tolerability of a new recombinant MCP-1 developed for limb ischemia

Positive phase I results for Pevion's malaria vaccine

PMA submission completed for Taxus Liberte paclitaxel-eluting coronary stent

Clinical application of LY-2124275 presented

Cervarix submitted for review in Europe

Fast track designation for ambrisentan

NicVAX awarded fast track designation

New antiinfective agents described in recent patents

Approvable letter for Preos

Daytrana NDA resubmission deemed Class I response

New anticancer agents revealed in recent patents

Paratek and Merck collaborate on novel antibiotic PTK-0796

Inhibition of Toll-like receptors, a promising approach for the treatment of lupus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...